Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Johnson & Johnson 3Q11 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Johnson & Johnson 3Q11

Pharmaceutical sales up 9%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Johnson & Johnson 3Q11

3Q Revenues: $16.0 billion (+7%)

3Q Earnings: $3.2 billion (-6%)

YTD Revenues: $48.8 billion (+6%)

YTD Earnings: $9.5 billion (-17%)

Comments: Worldwide Pharmaceutical sales were $6.0 billion in the quarter (+9%), but domestic sales were down 6%, impacted by generic competition for Levaquin. International sales increased 28%, which reflected an operational increase of 19% and a positive currency impact of 9%. Sales growth was attributed to recently launched products, Zytiga (for metastatic, castration-resistant prostate cancer), Stelara (for moderate to severe plaque psoriasis), Simponi (for moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) and Invega Sustenna (once-monthly, long-acting, injectable treatment for schizophrenia). International revenues were also boosted by the new split of Remicade sales. Prezista and Velcade also contributed to sales growth. 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters